Related Experiment Video
Updated: Jun 26, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases
Yeşim Ertan1, Murat Sezak, Bengü Demirağ
1Department of Pathology, Ege University Faculty of Medicine, Izmir, Turkey. yesim.ertan@ege.edu.tr
Purpose:
The aim of this study was to assess the prognostic value of MIB-1 and p53 in the pediatric medulloblastoma group.
Materials And Method:
Forty-two pediatric medulloblastoma cases diagnosed in a single institution during the past 10 years were evaluated. Follow-up data were available for 35 patients.
Results:
The immunoreactivity of MIB-1 ranged from 10% to 95%; p53 immunoreactivity was found in five cases. Of the 35 patients with follow-up, 34 patients received a combination of chemotherapy and radiotherapy, while one received chemotherapy alone. The follow-up period ranged from 5 to 64 months. Of the 35 patients, 21 were alive without any evidence of recurrent disease, three were alive with evidence of recurrent disease and 11 died of disease during follow-up. The mean survival for these 11 patients was 21.9+/-10.4 months. Of the 35 cases, 16 had MIB-1 value of 25% or lower and 19 had a value of 26% or more. Of the 16 cases with low MIB-1 value, six died of disease; of the 19 cases with high MIB-1 value, five died of disease. The statistical difference between MIB-1 and prognosis was not significant. Three of the 35 (8.5%) cases were found to be positive with p53 protein; no correlation was observed between p53 immunoreactivity and prognosis.
Conclusion:
It appears that the MIB-1 value and p53 immunoreactivity have no relation with prognosis in pediatric medulloblastomas. However, it is convenient to support these findings with large series.
Insights
This study found no significant link between MIB-1 or p53 protein levels and prognosis in pediatric medulloblastoma patients. Further research with larger patient groups is recommended to confirm these findings.
Area of Science:
- Pediatric Oncology
- Molecular Pathology
- Cancer Biomarkers
Background:
- Medulloblastoma is a common malignant brain tumor in children.
- Identifying prognostic markers is crucial for tailoring treatment strategies.
- MIB-1 (Ki-67) and p53 are proteins studied for their potential roles in tumor behavior.
Purpose of the Study:
- To evaluate the prognostic significance of MIB-1 and p53 expression in pediatric medulloblastoma.
- To determine if these markers correlate with patient outcomes.
Main Methods:
- Retrospective analysis of 42 pediatric medulloblastoma cases.
- Immunohistochemical assessment of MIB-1 and p53 expression.
- Correlation of marker levels with patient follow-up data (survival, recurrence).
Main Results:
- MIB-1 immunoreactivity varied widely (10-95%); p53 positivity was observed in 8.5% of cases.
- No statistically significant correlation was found between MIB-1 levels (high vs. low) and patient prognosis.
- p53 immunoreactivity also showed no observable correlation with prognosis.
Conclusions:
- MIB-1 and p53 expression do not appear to be related to prognosis in pediatric medulloblastoma.
- Larger cohort studies are needed to validate these preliminary findings.
